Integra Lifesciences Statistics
Integra Lifesciences (IL3) Stock Statistics & Valuation Metrics
Total Valuation
Integra Lifesciences has a market cap or net worth of EUR 1.04B. The enterprise value is EUR 2.97B.
- Market Cap
- EUR 1.04B
- Enterprise Value
- EUR 2.97B
Share Statistics
Integra Lifesciences has 77,800,980 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 77,800,980
- Owned by Insiders
- 3.26%
- Owned by Institutions
- 63.32%
Financial Efficiency
Integra Lifesciences’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is 1.91%.
- Return on Equity (ROE)
- -0.49
- Return on Assets (ROA)
- -0.14
- Return on Invested Capital (ROIC)
- 1.91%
- Return on Capital Employed (ROCE)
- 0.02
- Revenue Per Employee
- 369.38K
- Profits Per Employee
- -116.66K
- Employee Count
- 4,427
- Asset Turnover
- 0.45
- Inventory Turnover
- 1.60
Valuation Ratios
The current PE Ratio of Integra Lifesciences is 84.98. Integra Lifesciences’s PEG ratio is 0.13.
- PE Ratio
- 84.98
- PS Ratio
- 0.67
- PB Ratio
- 1.05
- Price to FCF
- 15.49
- Price to Operating Cash Flow
- 7.98
- PEG Ratio
- 0.13
Income Statement
In the last 12 months, Integra Lifesciences had revenue of 1.64B and earned -516.47M in profits. Earnings per share was -6.73.
- Revenue
- 1.64B
- Gross Profit
- 845.23M
- Operating Income
- 68.32M
- Pretax Income
- -563.50M
- Net Income
- -516.47M
- EBITDA
- -325.42M
- Earnings Per Share (EPS)
- -6.73
Cash Flow
In the last 12 months, operating cash flow was 140.40M and capital expenditures -68.82M, giving a free cash flow of 71.58M billion.
- Operating Cash Flow
- 140.40M
- Free Cash Flow
- 71.58M
- Free Cash Flow per Share
- 0.91
Dividends & Yields
Integra Lifesciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 6.45%
- Earnings Yield
- 1.16%
Stock Price Statistics
- Beta
- 0.97
- 52-Week Price Change
- 25.00%
- 50-Day Moving Average
- 12.64
- 200-Day Moving Average
- 12.22
- Relative Strength Index (RSI)
- 55.21
- Average Volume (3m)
- 100
Important Dates
Integra Lifesciences upcoming earnings date is Mar 03, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 21, 2026
- Next Earnings Date
- Mar 03, 2027
- Ex-Dividend Date
- ―
Financial Position
Integra Lifesciences as a current ratio of 2.54, with Debt / Equity ratio of 194.85%
- Current Ratio
- 2.54
- Quick Ratio
- 1.46
- Debt to Market Cap
- 1.95
- Net Debt to EBITDA
- -5.53
- Interest Coverage Ratio
- 0.79
Taxes
In the past 12 months, Integra Lifesciences has paid -47.03M in taxes.
- Income Tax
- -47.03M
- Effective Tax Rate
- 0.08
Enterprise Valuation
Integra Lifesciences EV to EBITDA ratio is 12.23, with an EV/FCF ratio of 39.94.
- EV to Sales
- 1.73
- EV to EBITDA
- 12.23
- EV to Free Cash Flow
- 39.94
- EV to Operating Cash Flow
- 20.36
Balance Sheet
Integra Lifesciences has EUR 311.93M in cash and marketable securities with EUR 2.00B in debt, giving a net cash position of -EUR 1.69B billion.
- Cash & Marketable Securities
- EUR 311.93M
- Total Debt
- EUR 2.00B
- Net Cash
- -EUR 1.69B
- Net Cash Per Share
- -EUR 21.73
- Tangible Book Value Per Share
- -EUR 7.40
Margins
Gross margin is 52.46%, with operating margin of 38.30%, and net profit margin of 0.79%.
- Gross Margin
- 52.46%
- Operating Margin
- 38.30%
- Pretax Margin
- 1.35%
- Net Profit Margin
- 0.79%
- EBITDA Margin
- 14.11%
- EBIT Margin
- 7.17%
Analyst Forecast
The average price target for Integra Lifesciences is EUR 13.29, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- EUR 13.29
- Price Target Upside
- 2.25% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 9
- Revenue Growth Forecast
- -4.23%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 3
- AI Score
- ―
